Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | DNLI |
---|---|---|
09:32 ET | 3866 | 21.87 |
09:34 ET | 700 | 21.79 |
09:36 ET | 700 | 22 |
09:38 ET | 3646 | 22.09 |
09:39 ET | 600 | 22.03 |
09:41 ET | 1845 | 22.12 |
09:43 ET | 200 | 22.14 |
09:45 ET | 431 | 22.19 |
09:48 ET | 3194 | 22.13 |
09:50 ET | 300 | 22.14 |
09:52 ET | 800 | 22.2 |
09:54 ET | 1500 | 22.13 |
09:56 ET | 2132 | 22.04 |
09:57 ET | 3000 | 22.025 |
09:59 ET | 300 | 22.025 |
10:01 ET | 2017 | 22.145 |
10:03 ET | 2188 | 22.09 |
10:06 ET | 2600 | 22.04 |
10:08 ET | 3633 | 22 |
10:10 ET | 200 | 21.97 |
10:12 ET | 1131 | 21.97 |
10:14 ET | 1400 | 22.03 |
10:15 ET | 1507 | 22.08 |
10:17 ET | 2500 | 22.11 |
10:19 ET | 881 | 22.115 |
10:21 ET | 5300 | 22.15 |
10:24 ET | 1400 | 22.17 |
10:26 ET | 300 | 22.22 |
10:28 ET | 2830 | 22.11 |
10:30 ET | 100 | 22.02 |
10:32 ET | 1659 | 21.985 |
10:33 ET | 301 | 22 |
10:35 ET | 721 | 22.04 |
10:37 ET | 2501 | 21.975 |
10:42 ET | 644 | 21.9 |
10:44 ET | 428 | 21.81 |
10:46 ET | 400 | 21.77 |
10:48 ET | 1378 | 21.71 |
10:50 ET | 600 | 21.69 |
10:51 ET | 400 | 21.69 |
10:53 ET | 1379 | 21.6 |
10:55 ET | 1066 | 21.59 |
10:57 ET | 543 | 21.55 |
11:00 ET | 1000 | 21.47 |
11:02 ET | 2445 | 21.5 |
11:04 ET | 400 | 21.5 |
11:08 ET | 1950 | 21.46 |
11:09 ET | 2000 | 21.47 |
11:11 ET | 703 | 21.485 |
11:13 ET | 200 | 21.495 |
11:15 ET | 2320 | 21.5 |
11:18 ET | 600 | 21.53 |
11:22 ET | 306 | 21.53 |
11:24 ET | 879 | 21.52 |
11:26 ET | 2400 | 21.495 |
11:27 ET | 500 | 21.45 |
11:29 ET | 989 | 21.4407 |
11:31 ET | 1326 | 21.435 |
11:33 ET | 300 | 21.4 |
11:36 ET | 1315 | 21.395 |
11:38 ET | 2020 | 21.375 |
11:40 ET | 600 | 21.405 |
11:42 ET | 200 | 21.41 |
11:45 ET | 1200 | 21.38 |
11:47 ET | 1742 | 21.36 |
11:49 ET | 1461 | 21.33 |
11:51 ET | 240 | 21.32 |
11:54 ET | 100 | 21.31 |
11:56 ET | 400 | 21.29 |
12:00 ET | 400 | 21.29 |
12:02 ET | 400 | 21.3 |
12:03 ET | 600 | 21.3 |
12:05 ET | 1411 | 21.325 |
12:07 ET | 1600 | 21.39 |
12:09 ET | 100 | 21.385 |
12:12 ET | 300 | 21.36 |
12:14 ET | 2716 | 21.41 |
12:16 ET | 685 | 21.435 |
12:18 ET | 3554 | 21.395 |
12:20 ET | 500 | 21.41 |
12:21 ET | 200 | 21.4 |
12:23 ET | 200 | 21.42 |
12:25 ET | 900 | 21.42 |
12:27 ET | 2000 | 21.46 |
12:30 ET | 1200 | 21.445 |
12:32 ET | 1200 | 21.46 |
12:34 ET | 1816 | 21.45 |
12:36 ET | 1448 | 21.46 |
12:38 ET | 3768 | 21.49 |
12:39 ET | 1400 | 21.49 |
12:41 ET | 1469 | 21.49 |
12:43 ET | 5376 | 21.45 |
12:45 ET | 4345 | 21.4 |
12:48 ET | 6138 | 21.38 |
12:50 ET | 7559 | 21.46 |
12:52 ET | 3790 | 21.41 |
12:54 ET | 11729 | 21.45 |
12:56 ET | 9476 | 21.385 |
12:57 ET | 7442 | 21.35 |
12:59 ET | 111798 | 21.3 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Denali Therapeutics Inc | 3.0B | -22.0x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Amicus Therapeutics Inc | 2.9B | -19.9x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -5.9x | --- |
Genmab A/S | 16.6B | 21.0x | +22.71% |
TG Therapeutics Inc | 2.9B | 85.2x | --- |
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -22.0x |
Price/Sales (TTM) | 10.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.